Urs Jaisli - Roche Holding Insider

RHHBY -- USA Stock  

USD 29.94  0.27  0.89%

We currently do not have informatin regarding Urs Jaisli. This executive tanure with Roche Holding AG is not currenlty determined.
Age: 61        
41 61 688 11 11  http://www.roche.com

Management Efficiency

The company has return on total asset (ROA) of 14.37 % which means that it generated profit of $14.37 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 31.85 % meaning that it generated $31.85 on every $100 dollars invested by stockholders.
The company has accumulated 19.15 B in total debt with debt to equity ratio (D/E) of 65.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Roche Holding AG has Current Ratio of 1.39 which is within standard range for the sector.

Similar Executives

Entity Summary

Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. The company was founded in 1896 and is headquartered in Basel, Switzerland. Roche Holding operates under Drug Manufacturers - Major classification in USA and traded on OTC Market. It employs 93734 people.Roche Holding AG (RHHBY) is traded on OTC Market in USA. It is located in Konzern Hauptsitz and employs 93,734 people.

Roche Holding AG Leadership Team

Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Silvia Ayyoubi, Head of Group HR
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Beatrice Mauro, Non-Executive Director
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics
Gottlieb Keller, General Counsel and Corporate Secretary
Urs Jaisli, Chief Compliance Officer
Daniel ODay, COO of Pharmaceuticals division
DeAnne Julius, Non-Executive Director
Karl Mahler, Head of Investor Relations
Andre Hoffmann, Non-Executive Vice Chairman of the Board
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Claudia Dyckerhoff, Non-Executive Director
Fritz Gerber, Honorary Chairman of the Board
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications
Julie Brown, Non-Executive Director
Richard Lifton, Non-Executive Director
Paul Bulcke, Non-Executive Director
Christoph Franz, Non-Executive Director
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office
Pius Baschera, Non-Executive Director
Peter Voser, Non-Executive Director
Bernard Poussot, Non-Executive Director
John Bell, Non-Executive Director
Andreas Oeri, Non-Executive Director
Alan Hippe, Chief Financial and IT Officer
F Hoffmann, IR Contact Officer
Severin Schwan, CEO and Executive Director
Anita Hauser, Non-Executive Director

Stock Performance Indicators

Current Sentiment - RHHBY

Roche Holding AG Investor Sentiment
Most of Macroaxis users are at this time bullish on Roche Holding AG. What is your perspective on investing in Roche Holding AG? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased over 30 shares of
a day ago
Traded for 17.39
Purchased few shares of
a day ago
Traded for 204.5
Purchased few shares of
a day ago
Traded for 64.17
Purchased few shares of
a day ago
Traded for 104.36
Purchased few shares of
a day ago
Traded for 112.41
Additionally take a look at Your Equity Center. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..